How should an adult with typical urinary tract infection symptoms be diagnosed and managed?

Diagnosis and Management of Urinary Tract Infections in Adults

For adults with typical UTI symptoms, diagnosis should be based primarily on clinical presentation, with treatment initiated promptly using first-line antimicrobials tailored to local resistance patterns and patient-specific factors.

Classification and Initial Assessment

The first critical step is distinguishing between uncomplicated and complicated UTIs, as this fundamentally drives management decisions 1.

Uncomplicated Cystitis

• Limited to nonpregnant, premenopausal women with no anatomic/functional urinary tract abnormalities or comorbidities 1
• Classic symptoms include: dysuria, urgency, frequency, suprapubic pain, and absence of vaginal discharge 1
• Diagnosis can be made on clinical grounds alone when typical symptoms are present—the focused history has high diagnostic accuracy without further testing 1, 2

When to Obtain Urine Studies

Urine culture is NOT routinely needed for uncomplicated cystitis in healthy women 1, 2. However, obtain urine culture with susceptibility testing in these situations 1:

• Suspected pyelonephritis (fever >38°C, flank pain, costovertebral angle tenderness)
• Symptoms persisting or recurring within 4 weeks after treatment
• Atypical presentation
• Pregnancy
• Men with UTI symptoms
• Elderly patients (≥65 years)

Dipstick/urinalysis has limited value: While absence of pyuria can help rule out infection, pyuria alone has exceedingly low positive predictive value as it indicates inflammation from many noninfectious causes 1. Do not diagnose UTI based solely on urinalysis findings 1.

Treatment of Uncomplicated Cystitis

First-Line Antimicrobial Therapy

Choose based on local resistance patterns, efficacy data, and antimicrobial stewardship principles 1:

Preferred agents:

• Nitrofurantoin monohydrate/macrocrystals: 100 mg twice daily for 5 days 1, 3

  • Excellent choice to spare systemically active agents
  • Effective with minimal resistance development

• Fosfomycin trometamol: Single 3-gram dose 1, 3

  • Convenient single-dose therapy

• Trimethoprim-sulfamethoxazole (TMP-SMX): 160/800 mg twice daily for 3 days 1, 3

  • Only if local E. coli resistance rates <20%
  • Increasing resistance limits first-line utility in many regions

• Trimethoprim alone: 200 mg twice daily for 3 days 1, 2

Avoid as first-line:

• Fluoroquinolones: Reserve for more invasive infections due to collateral damage and resistance concerns 1, 3
• β-lactams (amoxicillin-clavulanate, cefpodoxime): Less effective than other first-line options 3

Alternative: Symptomatic Treatment

For women with mild-to-moderate symptoms, symptomatic therapy with NSAIDs (e.g., ibuprofen) may be considered as an alternative to immediate antimicrobials, though this requires shared decision-making as complications risk is low but not zero 1. However, immediate antimicrobial therapy is generally recommended over delayed treatment 3.

Treatment Failure

If symptoms persist at treatment completion or recur within 2 weeks 1:

• Obtain urine culture with susceptibility testing
• Assume resistance to initial agent
• Retreat with 7-day course of different antimicrobial based on culture results

Treatment of Uncomplicated Pyelonephritis

Outpatient Oral Therapy

For mild-to-moderate cases without systemic toxicity 1:

• Fluoroquinolones (ciprofloxacin or levofloxacin): 5-7 days 1
• First-generation cephalosporins or TMP-SMX: 7 days if local resistance rates permit 1
• Avoid: Nitrofurantoin, oral fosfomycin, pivmecillinam—insufficient efficacy data for pyelonephritis 1

Inpatient Intravenous Therapy

For severe illness, inability to tolerate oral intake, or concern for sepsis 1:

• Ceftriaxone: Recommended empiric choice given low resistance and clinical effectiveness 1
• Fluoroquinolone IV
• Aminoglycoside ± ampicillin
• Extended-spectrum cephalosporin or penicillin
• Reserve carbapenems for documented multidrug-resistant organisms 1

Switch to oral therapy once clinically improved and able to tolerate oral intake, completing total 7 days of β-lactam therapy or 5-7 days of fluoroquinolone therapy 1.

Imaging Considerations

Obtain renal ultrasound to exclude obstruction or stones in patients with 1:

• History of urolithiasis
• Renal function impairment
• High urine pH
• Persistent fever after 72 hours of appropriate therapy

Obtain CT scan immediately if clinical deterioration occurs 1.

Special Populations

Men with UTI Symptoms

• Always treat with antimicrobials (unlike women where symptomatic therapy may be considered) 2
• Always obtain urine culture before treatment 2
• Consider urethritis and prostatitis in differential diagnosis 2
• Treatment duration: 7 days with TMP-SMX, trimethoprim, or nitrofurantoin 2
• Perform digital rectal examination to assess for prostate disease 1

Elderly Patients (≥65 years)

• Obtain urine culture with susceptibility testing to guide therapy 2
• Same first-line agents and durations as younger adults in nonfrail patients without relevant comorbidities 2
• Caution: Genitourinary symptoms in elderly women are not necessarily related to cystitis 1

Patients with Diabetes

Women with well-controlled diabetes and no voiding abnormalities presenting with acute cystitis should be treated identically to women without diabetes 3.

Asymptomatic Bacteriuria

Do NOT screen or treat asymptomatic bacteriuria in the following populations (strong recommendation) 1:

• Women without risk factors
• Patients with well-regulated diabetes
• Postmenopausal women
• Elderly institutionalized patients
• Patients with dysfunctional/reconstructed lower urinary tract
• Renal transplant recipients
• Patients before arthroplasty surgery
• Patients with recurrent UTIs

DO screen and treat asymptomatic bacteriuria in 1:

• Pregnant women: Use standard short-course treatment or single-dose fosfomycin 1
• Before urological procedures breaching the mucosa 1

Rationale: Asymptomatic bacteriuria may protect against symptomatic UTI; treatment risks selecting antimicrobial resistance and eradicating potentially protective strains 1.

Recurrent UTIs (≥3 UTIs/year or ≥2 in 6 months)

Non-Antimicrobial Prevention (Try First)

Stepwise approach—attempt interventions in this order 1:

1. Behavioral counseling: Avoid identified risk factors 1
2. Methenamine hippurate: Strong recommendation for women without urinary tract abnormalities 1
3. Increased fluid intake 2
4. Cranberry products 2
5. D-mannose: Weak evidence but may reduce recurrences 1
6. Endovesical hyaluronic acid ± chondroitin sulfate: For patients failing less invasive approaches (weak recommendation, needs further study) 1

Antimicrobial Prophylaxis

Use only when non-antimicrobial interventions have failed 1:

• Continuous prophylaxis or postcoital prophylaxis (strong recommendation) 1
• Counsel patients regarding side effects and resistance risks 1
• Self-administered short-term therapy for compliant patients (strong recommendation) 1

Critical Pitfalls to Avoid

1. Do not treat based on urinalysis alone—pyuria without symptoms does not equal infection 1
2. Do not obtain routine post-treatment cultures in asymptomatic patients 1
3. Do not use fluoroquinolones as first-line for simple cystitis—reserve for invasive infections 1, 3
4. Do not use nitrofurantoin or fosfomycin for pyelonephritis—inadequate tissue penetration 1
5. Do not screen for or treat asymptomatic bacteriuria in most populations—it may be protective 1
6. Do not assume "complicated UTI" without specific risk factors—this term lacks standardized definition and drives inappropriate broad-spectrum use 1